CXCL9 and colorectal carcinoma: In four CXC subfamily ligands (CXCL9, CXCL10, CXCL11, and CXCL13),the log-rank test showed that CRC patients with high expression significantly longer DFS than those with low expression (CXCL9: HR = 0.633, 95% CI = 0.452–0.888,p = 0.008; CXCL10: HR = 0.551, 95% CI = 0.392–0.775,p<0.001; CXCL11: HR = 0.574, 95% CI = 0.408–0.806,p = 0.001; CXCL13: HR = 0.574, 95% CI = 0.408–0.806,p = 0.001.